Special Issue "Role of NF-kappaB Pathway in Inflammation and Infection"
Deadline for manuscript submissions: 28 February 2022.
The Nuclear factor kappa B (NF-kB) pathway comprises a family of inducible transcription factors that serve as central regulators in essential physiological processes, such as cell growth, apoptosis, innate and adaptive immune response by modulating the expression of hundreds of genes encoding multiple cytokines and chemokines, their receptors, molecules involved in immune recognition, antigen presentation, cell adhesion and migration.
Recent studies indicate that NF-kB may be central to the immune hyperactivation and cytokine/chemokine storm observed during acute stage COVID-19. There is growing evidence that severity of clinical manifestations during COVID-19 is higher preferably in elderly persons and in connection with various comorbidities, such as diabetes and cardiovascular diseases where NF-kB is known to play a central role. Chronical activation of NF-kB pathway is involved in the pathogenesis of numerous chronic diseases, including rheumatoid arthritis, atherosclerosis, diabetes, and Alzheimer’s disease. Importantly, also aging is associated with increased NF-kB activation. In addition, NF-kB plays a pivotal role in the pathogenesis of various acute situations, such as sepsis, acute respiratory syndrome, and reactivity to CAR-T cell therapy triggering pro-inflammatory cytokine release and procoagulation activation.
Altogether, these data indicate that the NF-kB pathway may be highly relevant in the immune pathological mechanisms of COVID-19 and an interesting target for pharmacological intervention and re-purposing of drugs for treatment.
The scope of this special issue is to summarize and enlarge the knowledge in NF-kB pathway and its involvement in immunological and pathological processes of COVID-19.
Topics include, but are not limited to:
- New aspects of NF-kB signalling pathways and their correlation to immunology and pathophysiology of COVID-19
- Epidemiological aspects of NF-kB associated to COVID-19 and other infectious and/or non-communicable diseases
- Translational research, pharmacological and medical interventions with NF-kB pathway as a therapeutic target for COVID-19 treatment
Ralf Kircheis, MD PhD
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Innate and adaptive immune response
- Cytokine and chemokine
- Complement and coagulation
- Obesity and diabetes
- Viral disease